Retina Health Series

Vitreomacular Traction Syndrome

The vitreous humor is a transparent, gel-like material that fills the space within the eye between the lens and the retina. The vitreous is encapsulated in a thin shell called the vitreous cortex, and the cortex in young, healthy eyes is usually sealed to the retina.

As the eye ages, or in certain pathologic conditions, the vitreous cortex can pull away from the retina, leading to a condition known as posterior vitreous detachment (PVD). This detachment usually occurs as part of the normal aging process.

There are instances where a PVD is incomplete, leaving the vitreous partially attached to the retina, and causing tractional (pulling) forces that can cause anatomical damage. The resulting condition is called vitreomacular traction (VMT) syndrome.

VMT syndrome can lead to different maculopathies or disorders in the macular area (at the center of the retina), such as full- or partial-thickness macular holes, epiretinal membranes, and cystoid macular edema. These disorders are often associated with reduced sharpness of vision (visual acuity) or other visual complications.

Download Fact Sheet

Symptoms in detail

The most common symptoms experienced by patients with VMT syndrome are: 

  • Decreased sharpness of vision
  • Photopsia, when a person sees flashes of light in the eye
  • Micropsia, when objects appear smaller than their actual size
  • Metamorphopsia, when vision is distorted to make a grid of straight lines appear wavy or blank

Some of these symptoms can be mild and develop slowly; however, chronic tractional effects can lead to continued visual loss if left untreated. In some cases, a distortion of a visual picture could be experienced without necessarily having a reduction in sharpness of vision.


Age-related degeneration of the gel-like vitreous humor leads to the formation of pockets of fluid within the vitreous, causing contraction and loss of volume. The separation of the vitreous gel from the retina occurs as a result of the gel becoming liquid (liquefaction) and the continuous anterior-posterior (front-back) and tractional forces stretching on the macula over time.

Weakening of the attachments of the vitreous cortex and the internal limiting membrane (ILM) of the retina could also lead to partial detachment of the posterior hyaloid membrane, leading to PVD and potentially VMT.

Risk factors

VMT syndrome is most common in older adults and women due to age-related vitreous changes and vitreous liquefaction associated with declining post-menopausal estrogen levels, respectively. 

  • Other risk factors include:
  • High myopia (extreme nearsightedness)
  • Exudative (wet) age-related macular degeneration
  • Diabetic macular edema
  • Retinal vein occlusion
  • Diabetic retinopathy

Diagnostic testing

Optical coherence tomography (OCT) is a commonly used and recommended method to noninvasively identify and monitor VMT syndrome. This technology captures cross-sectional images of the retinal layers, including the surface, and allows physicians to evaluate the degree to which vitreomacular tractional forces are distorting the retinal structure.

A dynamic B-scan ultrasound examination could also be performed to provide a detailed evaluation of the vitreoretinal interface.

SD-OCT appearance of right eye showing vitreomacular traction

SD-OCT appearance of right eye following vitrectomy surgery

Images courtesy of Alex P. Hunyor, MD

Treatment and prognosis

There are currently 3 main options for treating VMT syndrome.

  1. Watchful waiting and regular monitoring with OCT is often used for patients whose symptoms do not warrant active intervention. Some cases of VMT may spontaneously resolve.
  2. For patients whose symptoms are severe enough to require intervention, pars plana vitrectomy surgery is one treatment option. The procedure involves the manual release of vitreous attachment and alleviation of traction, but it is invasive and inconvenient to most patients. Therefore vitrectomy is reserved for patients who are at risk for severe visual disturbances and/or central blindness. Some studies have shown that shorter duration of symptoms results in better prognosis when the surgical treatment is employed.
  3. Ocriplasmin (Jetrea®), a recombinant truncated form of human plasmin, is a pharmacologic option for treating VMT syndrome. Clinical trials demonstrated the efficacy and safety of a single intravitreal injection of ocriplasmin for the treatment of patients with symptomatic vitreomacular adhesion, and/or vitreomacular traction. Ocriplasmin is therefore a treatment option for some patients who have vitreomacular traction but who are not candidates for surgery.

Most patients with VMT maintain good visual acuity in the affected eye, even if treatment is required.



Sophie J. Bakri, MD  Audina Berrocal, MD 
Antonio Capone, Jr., MD Netan Choudhry, MD, FRCS-C
Thomas Ciulla, MD, MBA  Pravin U. Dugel, MD
Geoffrey G. Emerson, MD, PhD Roger A. Goldberg, MD, MBA
Darin R. Goldman, MD

Dilraj S. Grewal, MD

Larry Halperin, MD Vincent S. Hau, MD, PhD
Suber S. Huang, MD, MBA Mark S. Humayun, MD, PhD 
Peter K. Kaiser, MD M. Ali Khan, MD
Anat Loewenstein, MD  Mathew J. MacCumber, MD, PhD
Maya Maloney, MD Hossein Nazari, MD 
Oded Ohana, MD, MBA George Parlitsis, MD 
Jonathan L. Prenner, MD Gilad Rabina, MD
Carl D. Regillo, MD, FACS Andrew P. Schachat, MD 

Michael Seider, MD

Eduardo Uchiyama, MD 
Allen Z. Verne, MD Yoshihiro Yonekawa, MD

John T. Thompson, MD

Tim Hengst

Copyright 2016 The Foundation of the American Society of Retina Specialists. All rights reserved.